ERJ Open Research最新文献_第10页

Through the MIRRA and what we found there. 通过 MIRRA 和我们在那里发现的东西。

IF 4.3 3区医学

ERJ Open Research Pub Date : 2024-01-08 eCollection Date: 2024-01-01 DOI: 10.1183/23120541.00825-2023

Shigeharu Ueki

引用次数: 0

Vocal cord dysfunction/inducible laryngeal obstruction cannot be diagnosed from symptoms. 声带功能障碍/诱发性喉阻塞不能从症状中诊断出来。

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-27 eCollection Date: 2023-11-01 DOI: 10.1183/23120541.00707-2023

Grace Yap, Laurence E Ruane, Kais Hamza, Elizabeth Leahy, Adriana Avram, Malcolm Baxter, Joo Koh, Philip G Bardin, Paul Leong

引用次数: 0

Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study. 使用电子日记和腕带加速度计检测慢性阻塞性肺病的病情加重和活动量：一项可行性研究。

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-27 eCollection Date: 2023-11-01 DOI: 10.1183/23120541.00366-2023

Lydia J Finney, Stefan Avey, Dexter Wiseman, Anthony Rowe, Matthew J Loza, Patrick Branigan, Christopher S Stevenson, Frédéric Baribaud, Jadwiga A Wedzicha, Ioannis Pandis, Gavin C Donaldson

{"title":"Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study.","authors":"Lydia J Finney, Stefan Avey, Dexter Wiseman, Anthony Rowe, Matthew J Loza, Patrick Branigan, Christopher S Stevenson, Frédéric Baribaud, Jadwiga A Wedzicha, Ioannis Pandis, Gavin C Donaldson","doi":"10.1183/23120541.00366-2023","DOIUrl":"10.1183/23120541.00366-2023","url":null,"abstract":"Background: Early and accurate identification of acute exacerbations of COPD may lead to earlier treatment and prevent hospital admission. Electronic diaries have been developed for symptom monitoring and accelerometers to monitor activity. However, it is unclear whether this technology is usable in the COPD population. This study aimed to assess the feasibility of an electronic diary (eDiary) for symptom reporting using the MoreCare app and activity monitoring with the Garmin Vivofit 2 in COPD.Methods: Participants were recruited from the London COPD Cohort. Participants were provided a Garmin Vivofit 2 activity monitor and an android tablet with the MoreCare app for a period of 3 months.Results: 25 COPD patients were recruited (mean±sd age 70.8±7.1 years, forced expiratory volume in 1 s (FEV1) 49.8±14.8% predicted). Age, gender, disease severity and exacerbation frequency had no impact on eDiary compliance. There was a moderate positive correlation between median daily very active minutes and FEV1 % pred (ρ=0.62, p=0.005). Daily step counts decreased during the initial 7 days of exacerbation and recovery compared to a pre-exacerbation baseline. A decision-tree model identified change in sputum colour, change in step count, severity of cold, exacerbation history and use of rescue medication as the most important predictors of acute exacerbations of COPD in this cohort.Conclusions: Symptom and activity monitoring using digital technology is feasible in COPD. Further large-scale digital health studies are needed to assess whether eDiaries can be used to identify patients at risk of exacerbation and guide early intervention.","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"9 6","pages":""},"PeriodicalIF":4.6,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Feasibility and value of a domiciliary spirometry programme in the assessment of severe asthma: a real-world evaluation. 家庭肺活量测量计划在评估严重哮喘中的可行性和价值：真实世界评估。

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-27 eCollection Date: 2023-11-01 DOI: 10.1183/23120541.00635-2023

Zander Williams, James H Hull, Yueqi Ge, Jo Ming, Cara Roberts, Serena Rhamie, Pujan H Patel

{"title":"Feasibility and value of a domiciliary spirometry programme in the assessment of severe asthma: a real-world evaluation.","authors":"Zander Williams, James H Hull, Yueqi Ge, Jo Ming, Cara Roberts, Serena Rhamie, Pujan H Patel","doi":"10.1183/23120541.00635-2023","DOIUrl":"10.1183/23120541.00635-2023","url":null,"abstract":"Background: Domiciliary spirometry (DS) is a novel tool that is widely employed in the assessment of respiratory disease. We assessed real-world feasibility, effectiveness and value of a physiologist-led home spirometry programme in patients with treatment-refractory severe asthma.Methods: Patients were referred and provided with a hand-held DS device. Patients completed baseline measurements in a physiologist-led virtual clinic and were instructed to provide further values during any periods of respiratory symptoms. Outcome measures included prevalence of new obstructed events, DS adherence and uptake of this approach.Results: 112 patients were enrolled from November 2020 to January 2023. 102 individuals, mean±sd age 44±13 years (86% female) with median (IQR) forced expiratory volume in 1 s % predicted 88% (77-97%), successfully recorded baseline spirometry values. During follow-up (24 months), 11 (11%) were identified with new obstructive spirometry and were subsequently able to be commenced on biologic therapy. Patient engagement was poor with median (IQR) of 4 (2-6) attempts of contact made before baseline values were recorded, and 2 (1-3) attempts required to record technically acceptable values. Continued DS use was suboptimal; 34% failed to use their device after baseline and only 10% continued at the end of the study period. The cost of DS measurements was greater than a single hospital-based visit but enables multiple event capture.Conclusion: Overall, DS measurement uptake was poor, with a minority of patients continuing to use the device at the end of the study period. However, for those that engage, DS provides an alternative approach to traditional hospital-based spirometry measurements that can alter clinical management.","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"9 6","pages":""},"PeriodicalIF":4.6,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort 在研究中反映间皮瘤患者的真实情况：ASSESS-meso 队列基线特征中期报告

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-21 DOI: 10.1183/23120541.00467-2023

R. Conway, Natalie Smith, William Cooper, Geraldine Lynch, S. Patole, J. Symonds, Anthony Edey, Nick A Maskell, A. Bibby

{"title":"Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort","authors":"R. Conway, Natalie Smith, William Cooper, Geraldine Lynch, S. Patole, J. Symonds, Anthony Edey, Nick A Maskell, A. Bibby","doi":"10.1183/23120541.00467-2023","DOIUrl":"https://doi.org/10.1183/23120541.00467-2023","url":null,"abstract":"Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multi-centre, prospective, mesothelioma cohort study (ISRCTN61861764). This pre-specified interim analysis, conducted when recruitment reached 25% of target, summarised participant characteristics and evaluated external validity through comparison with real-world and clinical trial cohorts.The study took place at 14 hospitals across the UK. People diagnosed with mesothelioma, at any anatomical site, were eligible. Clinical, radiological and biochemical data were collected at enrolment. In this interim report, the external validity of the cohort was investigated through comparison of baseline demographic data with populations included in the 2020 UK National Mesothelioma Audit (real-world cohort), and CHECKMATE-743 and MAPS trials (clinical trial cohorts).Between 07/04/2017–01/03/2022, 244 patients were enrolled. The cohort was predominantly male (195/244; 80%) with median age of 74 years. Pleural disease and epithelioid sub-types were most prevalent. ASSESS-meso participants were more similar to the real-world population with regards age, performance status, disease site and stage than the clinical trial population. ASSESS-meso participants were more likely to be formally staged and less likely to have undifferentiated histology compared with the real-world cohort, possibly reflecting high rates of discussion of ASSESS-meso participants at regional mesothelioma MDTs. As expected, poorer performance status, non-epithelioid histology and neutrophil-lymphocyte ratio were associated with shorter survival in the adjusted analysis.ASSESS-meso is representative of the UK mesothelioma population. Future outputs from the cohort will help characterise different mesothelioma phenotypes with high external validity.","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"4 7","pages":""},"PeriodicalIF":4.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138949115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated transaminases in congenital central hypoventilation syndrome (CCHS) 先天性中枢通气不足综合征（CCHS）转氨酶升高

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-21 DOI: 10.1183/23120541.00658-2023

Rachel Y. Wang, Victoria S. Wang, Thomas G. Keens, Yan Chai, Nisreen Soufi, Iris A. Perez

引用次数: 0

The many faces of copd in real life: a longitudinal analysis of the novelty cohort 现实生活中的多面 copd：对新奇队列的纵向分析

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-21 DOI: 10.1183/23120541.00895-2023

Alvar Agustí, R. Hughes, Eleni Rapsomaki, B. Make, Ricardo del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzén, Jørgen Vestbo, Hana Mullerova

{"title":"The many faces of copd in real life: a longitudinal analysis of the novelty cohort","authors":"Alvar Agustí, R. Hughes, Eleni Rapsomaki, B. Make, Ricardo del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzén, Jørgen Vestbo, Hana Mullerova","doi":"10.1183/23120541.00895-2023","DOIUrl":"https://doi.org/10.1183/23120541.00895-2023","url":null,"abstract":"The diagnosis of Chronic Obstructive Pulmonary Disease (COPD) requires the demonstration of non-fully reversible airflow limitation by spirometry in the appropriate clinical context. Yet, there are patients with symptoms and relevant exposures suggestive of COPD with either normal spirometry (pre-COPD) or Preserved Ratio but Impaired Spirometry (PRISm). Their prevalence, clinical characteristics and associated outcomes in a real-life setting are unclear.To investigate them, we studied 3183 patients diagnosed of COPD by their attending physician included in the NOVELTY study (NCT02760329), a global, 3-year, observational, real-life cohort that included patients recruited from both primary and specialist care clinics in 18 countries.We found that:(1)about a quarter of patients diagnosed with (and treated for) COPD in real-life did not fulfil the spirometric diagnostic criteria recommended by GOLD, and could be instead categorized as pre-COPD (13%) or PRISm (14%);(2)disease burden (symptoms and exacerbations) was highest in GOLD 3–4 patients (exacerbations per person-year [PPY]: 0.82) and lower but similar in those in GOLD 1–2, pre-COPD and PRISm (exacerbations PPY range: 0.27-0.43);(3)lung function decline was highest in pre-COPD and GOLD 1–2, and much less pronounced in PRISm and GOLD 3-4;(4); PRISm and pre-COPD were not stable diagnostic categories and change substantially over time; and,(5)all-cause mortality was highest in GOLD 3–4, lowest in pre-COPD, and intermediate and similar in GOLD 1–2 and PRISm.Patients diagnosed COPD in a real-life clinical setting present great diversity in symptom burden, progression, and survival, warranting medical attention.","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"7 7","pages":""},"PeriodicalIF":4.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138949330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endothelial to mesenchymal transition is an active process in smokers and patients with early COPD contributing to pulmonary arterial pathology 内皮向间充质转化是吸烟者和早期慢性阻塞性肺疾病患者的一个活跃过程，可导致肺动脉病变

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-21 DOI: 10.1183/23120541.00767-2023

P. Bhattarai, Wenying Lu, A. Hardikar, Surajit Dey, A. Gaikwad, Affan Mahmood Shahzad, C. Chia, Andrew Williams, G. Singhera, T. Hackett, M. Eapen, S. Sohal

{"title":"Endothelial to mesenchymal transition is an active process in smokers and patients with early COPD contributing to pulmonary arterial pathology","authors":"P. Bhattarai, Wenying Lu, A. Hardikar, Surajit Dey, A. Gaikwad, Affan Mahmood Shahzad, C. Chia, Andrew Williams, G. Singhera, T. Hackett, M. Eapen, S. Sohal","doi":"10.1183/23120541.00767-2023","DOIUrl":"https://doi.org/10.1183/23120541.00767-2023","url":null,"abstract":"We have previously reported pulmonary arterial remodelling in smokers and patients with early COPD, which can be attributed to EndMT. In this study, we aimed to evaluate if EndMT is an active mechanism in smokers and COPD.Immunohistochemical staining for EndMT biomarkers, CD-31, N-cadherin, Vimentin and S100A4, was done on lung resections from 49 subjects. Fifteen were non-smoker-controls (NC), six normal lung function smokers (NLFS), nine patients with small-airway diseases (SAD), nine mild-moderate COPD-current smokers (COPD-CS) and ten COPD-ex-smokers (COPD-ES). Pulmonary arteries were analysed using Image ProPlus software v7.0.We noted reduced junctional CD31-positive endothelial cells (p<0.05) in intimal layer of all smoking groups compared to NC. Compared to NC, increased abundance of mesenchymal markers N-cadherin (p<0.05) and Vimentin (p<0.001) was observed in all smoking groups and across all arterial sizes, except for N-Cadherin in large arterial size for COPD-CS. Abundance of S100A4 correlated with arterial thickness (r= 0.29, 0.33, 0.35; p=0.05, 0.03, 0.02 respectively for small, medium, and large arteries). Vimentin in the small arterial wall negatively correlated with FEV1/ FVC and FEF25–75% (r= −0.35, −0.34; p= 0.02,0.03, respectively), while increased cytoplasmic CD-31 abundance in the intimal layer of medium and large arteries negatively correlated with DLCO-predicted (r= −0.35, −0.39; p=0.04, 0.03 respectively).This is the first study showing the acquisition of mesenchymal traits by pulmonary endothelial cells from NLFS, SAD and mild-moderate COPD patients through EndMT. This informs the potential early origins of pulmonary hypertension in smokers and patients with early COPD.","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"27 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138951791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amyloid-β and caspase-1 are indicators of sepsis and organ injury 淀粉样蛋白-β和 Caspase-1 是败血症和器官损伤的指标

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-21 DOI: 10.1183/23120541.00572-2023

Amanda N Tuckey, Arcole Brandon, Y. Eslaamizaad, Waqar Siddiqui, Talha Nawaz, Christopher Clarke, Erica Sutherland, Veronica Williams, Domenico Spadafora, Robert A. Barrington, Diego F. Alvarez, Madhuri S. Mulekar, Jon D. Simmons, Brian W. Fouty, J. Audia

{"title":"Amyloid-β and caspase-1 are indicators of sepsis and organ injury","authors":"Amanda N Tuckey, Arcole Brandon, Y. Eslaamizaad, Waqar Siddiqui, Talha Nawaz, Christopher Clarke, Erica Sutherland, Veronica Williams, Domenico Spadafora, Robert A. Barrington, Diego F. Alvarez, Madhuri S. Mulekar, Jon D. Simmons, Brian W. Fouty, J. Audia","doi":"10.1183/23120541.00572-2023","DOIUrl":"https://doi.org/10.1183/23120541.00572-2023","url":null,"abstract":"Sepsis is a life-threatening condition that results from a dysregulated host response to infection, leading to organ dysfunction. Despite the prevalence and associated socioeconomic costs, treatment of sepsis remains limited to antibiotics and supportive care, and a majority of intensive care unit (ICU) survivors develop long-term cognitive complications post- discharge. The present study identifies a novel regulatory relationship between amyloid-β (Aβ) and the inflammasome-caspase-1 axis as key innate immune mediators that define sepsis outcomes.Medical ICU patients and healthy individuals were consented for blood and clinical data collection. Plasma cytokine, caspase-1, and Aβ levels were measured. Data were compared against indices of multi-organ injury and other clinical parameters. Additionally, recombinant proteins were testedin vitroto examine the effect of caspase-1 on a functional hallmark of Aβ, namely aggregation.Plasma caspase-1 levels displayed the best predictive value in discriminating ICU patients with sepsis from non-infected ICU patients (AUROC=0.7080). Plasma caspase-1 and the 40 amino acid Aβ isoform (Aβx−40) showed a significant positive correlation and Aβx-40associated with organ injury. Additionally, Aβ plasma levels continued to rise from time of ICU admission to 7-days post-admission.In silico, Aβ harbors a predicted caspase-1 cleavage site, andin vitrostudies demonstrated that caspase-1 cleaved Aβ to inhibit its auto-aggregation, suggesting a novel regulatory relationship.Aβx-40and caspase-1 are potentially useful early indicators of sepsis and its attendant organ injury. Additionally, Aβx-40has emerged as a potential culprit in the ensuing development of post-ICU-syndrome.","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"5 12","pages":""},"PeriodicalIF":4.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138950625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phenotypes and treatment outcomes in idiopathic pulmonary arterial hypertension (IPAH) patients with comorbidities 有合并症的特发性肺动脉高压 (IPAH) 患者的表型和治疗效果

IF 4.6 3区医学

ERJ Open Research Pub Date : 2023-12-21 DOI: 10.1183/23120541.00668-2023

Dirk Skowasch, Hans Klose, Ralf Ewert, Heinrike Wilkens, Manuel Richter, Stephan Rosenkranz, Gesine Setzer, Ekkehard Grünig, M. Halank

引用次数: 0